02 - Experimental Therapeutics

02 - 实验疗法

• 批准号: 10629235
• 负责人: Eddy Shih-Hsin Yang
• 金额: $ 10.44万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-28 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10629235
• 关键词: Abbreviations; Alabama; Anatomy; Basic Cancer Research; Basic Science; Bioinformatics; Biometry; Cancer Biology; Cancer Center Support Grant; Cancer Control; Cancer Patient; Catchment Area; Chemoprevention; Clinical; Clinical Research; Clinical Trials; Collaborations; Combined Modality Therapy; Communities; Community Outreach; Comprehensive Cancer Center; Cyclotrons; DNA Repair; Diagnostic; Discipline; Disease; Disease Progression; Drug Targeting; Drug resistance; EGFR inhibition; Early Therapeutic-Clinical Trials Network; Educational workshop; Enrollment; Epidermal Growth Factor Receptor; Flow Cytometry; Freedom; Funding; Future; Genetic Engineering; Genomics; Goals; Grant; Granzyme; Growth; Head and Neck Cancer; Hypoxia; Image; Imaging Techniques; Immunotherapy; Industry; Infrastructure; Institution; Investigational Therapies; Investments; Journals; Laboratories; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of prostate; Malignant neoplasm of urinary bladder; Mentorship; Metabolism; Microscopy; Modeling; Molecular; Multiple Myeloma; Non-Small-Cell Lung Carcinoma; Obesity; PARP inhibition; Patient Recruitments; Patient Selection; Patients; Peer Review; Persons; Pharmaceutical Chemistry; Phase; Phase I/II Trial; Physicians; Population Sciences; Pre-Clinical Model; Prevention; Preventive Clinical Trial; Proteomics; Publications; Quality of life; Radiochemistry; Radiopharmaceuticals; Research; Research Activity; Research Personnel; Research Project Grants; Resistance development; Resource Sharing; Resources; Schools; Scientist; Site; Strategic Planning; Therapeutic; Therapeutic Agents; Therapeutic Clinical Trial; Therapeutic Trials; Tissue Procurements; Training; Transgenic Organisms; Translating; Translational Research; Treatment Efficacy; Underrepresented Minority; Underserved Population; Validation; Work; animal imaging; anticancer research; bench to bedside; cGMP production; cancer prevention; cancer therapy; cancer type; checkpoint inhibition; clinical translation; community engagement; design; drug candidate; drug development; drug discovery; effective therapy; high throughput screening; human imaging; imaging agent; imaging biomarker; imaging facilities; improved; in vivo; industry partner; inhibitor; innovation; interdisciplinary collaboration; investigator-initiated trial; malignant breast neoplasm; medically underserved; melanoma; member; microbiome; molecular imaging; neuro-oncology; new therapeutic target; next generation; novel; novel strategies; novel therapeutic intervention; novel therapeutics; patient response; phase 1 study; phase III trial; pre-clinical; prevent; prevention clinical trial; programs; quantitative imaging; single cell analysis; targeted treatment; therapeutic development; translational cancer research; translational scientist; treatment response; triple-negative invasive breast carcinoma; tumor immunology; working group

ABSTRACT – EXPERIMENTAL THERAPEUTICS (ET) PROGRAM Overview and Goals: The ET Program is the major translational/clinical research engine of the O'Neal with the goals of identifying novel targets and developing new imaging techniques that can inform innovative therapeutic strategies and provide cancer patients with an enhanced opportunity for improved survival, increased freedom from disease progression, and improved quality of life. Research Highlights: Discovery of new pre-clinical targets such as LIMK2 and PAK4, their in vivo validation in pre-clinical models and medicinal chemistry efforts to develop clinical grade inhibitors to these targets will provide novel therapeutic opportunities for triple-negative breast cancer (TNBC) and bladder cancer patients, with direct implications for other cancer types in our catchment area. Advances in imaging markers of patient response to immunotherapies, including hypoxia and granzyme B, have led to clinical trials in breast cancer, melanoma, and non-small cell lung cancer, all of which are of importance in our catchment area. Successful inter- and intra-programmatic collaborative bench to bedside efforts continue to result in clinical translation, including novel combinations with EGFR and PARP inhibition in TNBC or EGFR and DNA repair checkpoint inhibition in head and neck cancer. Program Activities: ET co-leaders work closely with O'Neal leadership to enable intra- and inter-programmatic collaborations through program activities enhanced by SPORE (Cervical cancer; P50 CA098252) and P01 funding (Cancer Prevention; P01 CA210946), significant collaborations with Southern Research through the Alabama Drug Discovery Alliance, and partnerships with industry. Strong collaborations with national consortia have continued, including the NCI NCTN Lead Academic Partnership Site grant (UG1 CA233330) and the Translational Breast Cancer Research Consortium. Members: The program has 60 members from 14 departments and 3 schools. NCI funding is $3.6M, cancer-relevant, peer-reviewed funding is $7.8M, and total cancer-relevant funding is $23M. 2,065 patients were enrolled in therapeutic trials over the current CCSG cycle, including 12% to investigator-initiated trials, 31% to pilot/Phase I studies, 10% to Phase I/II trials, and 37% to Phase III trials. The program had 1,123 publications over the current CCSG cycle including 34% inter-programmatic, 24% intra-programmatic, 68% resulting from collaborations with other institutions, and 13% in journals with an impact factor of 9 or greater. Future Directions: We plan to enhance current strengths in O'Neal cross-cutting research themes as laid out in the strategic plan, namely obesity and metabolism in cancer, cancer immunology, imaging, target identification and therapeutic development. We will work with the office of Community Outreach and Engagement to leverage recent support e.g., Bridge the Transdisciplinary Cancer Research Continuum supplement (P30 CA013148-48S6), CATCH-UP ETCTN supplement (P30 CA013148-48S3), Genentech AIR grant, and institutional infrastructure to bring the newest innovative cancer treatments to the underserved population of Alabama.

摘要-实验治疗（ET） 概述和目标：ET计划是奥尼尔的主要转化/临床研究引擎， 目标是确定新的靶点和开发新的成像技术， 为癌症患者提供更好的生存机会，增加自由， 从疾病的进展，并改善生活质量。研究重点：发现新的临床前 LIMK 2和PAK 4等靶点，它们在临床前模型中的体内验证以及药物化学方面的努力， 开发针对这些靶点的临床级抑制剂将为三阴性肿瘤提供新的治疗机会。 乳腺癌（TNBC）和膀胱癌患者，直接影响我们流域的其他癌症类型 区患者对免疫治疗反应的成像标志物的进展，包括缺氧和颗粒酶B， 已经导致了乳腺癌、黑色素瘤和非小细胞肺癌的临床试验，所有这些都很重要。 在我们的集水区。继续开展成功的方案间和方案内合作工作 导致临床转化，包括在TNBC或EGFR中与EGFR和PARP抑制的新型组合 和DNA修复检查点抑制。项目活动：ET共同领导人密切合作 在奥尼尔的领导下，通过项目活动实现项目内和项目间的合作 通过SPORE（宫颈癌; P50 CA 098252）和P01资金（癌症预防; P01 CA 210946）加强， 通过亚拉巴马药物发现联盟与南方研究公司进行了重大合作， 与工业界的伙伴关系。与国家财团的强有力的合作继续进行，包括NCI NCTN 领导学术合作伙伴网站赠款（UG 1 CA 233330）和转化乳腺癌研究 财团成员：该方案有来自14个部门和3所学校的60名成员。NCI资金为360万美元， 癌症相关的同行评审资金为780万美元，癌症相关资金总额为2300万美元。2,065名患者 在当前的CCSG周期中，入组治疗试验的患者中，包括12%的患者参加了药物启动的试验，31%的患者参加了药物启动的试验。 试验/I期研究，10%进入I/II期试验，37%进入III期试验。该计划有1，123份出版物 在当前CCSG周期内，包括34%的项目间，24%的项目内，68%的项目 与其他机构的合作，13%的期刊影响因子为9或更高。未来发展方向： 我们计划加强奥尼尔在战略计划中提出的跨领域研究主题的现有优势， 即肥胖和癌症代谢、癌症免疫学、成像、靶点识别和治疗 发展我们将与社区外展和参与办公室合作，利用最近的支持 例如，在一个实施例中，桥接跨学科癌症研究连续体补充（P30 CA 013148 - 48 S6），追赶 ETCTN补充（P30 CA 013148 - 48 S3），Genentech AIR赠款和机构基础设施， 为亚拉巴马的弱势群体提供最新的创新癌症治疗。